NLTXNeurogene Inc.

Nasdaq neoleukin.com


$ 35.44 $ -0.11 (-0.31 %)    

Tuesday, 20-Aug-2024 15:59:52 EDT
QQQ $ 480.15 $ -1.01 (-0.21 %)
DIA $ 408.54 $ -0.55 (-0.13 %)
SPY $ 558.65 $ -0.91 (-0.16 %)
TLT $ 98.68 $ 0.78 (0.8 %)
GLD $ 232.46 $ 0.85 (0.37 %)
$ 35.7
$ 34.94
$ 35.15 x 100
-- x --
$ 34.12 - $ 35.74
$ 12.49 - $ 53.00
92,230
na
9.69M
$ 3.64
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-09-2024 06-30-2024 10-Q
2 05-10-2024 03-31-2024 10-Q
3 03-18-2024 12-31-2023 10-K
4 11-14-2023 09-30-2023 10-Q
5 08-10-2023 06-30-2023 10-Q
6 05-08-2023 03-31-2023 10-Q
7 03-20-2023 12-31-2022 10-K
8 11-14-2022 09-30-2022 10-Q
9 08-09-2022 06-30-2022 10-Q
10 05-09-2022 03-31-2022 10-Q
11 03-01-2022 12-31-2021 10-K
12 11-04-2021 09-30-2021 10-Q
13 08-05-2021 06-30-2021 10-Q
14 05-12-2021 03-31-2021 10-Q
15 03-25-2021 12-31-2020 10-K
16 11-09-2020 09-30-2020 10-Q
17 08-12-2020 06-30-2020 10-Q
18 05-06-2020 03-31-2020 10-Q
19 03-12-2020 12-31-2019 10-K
20 11-13-2019 09-30-2019 10-Q
21 08-01-2019 06-30-2019 10-Q
22 05-07-2019 03-31-2019 10-Q
23 03-07-2019 12-31-2018 10-K
24 11-07-2018 09-30-2018 10-Q
25 08-08-2018 06-30-2018 10-Q
26 05-08-2018 03-31-2018 10-Q
27 03-12-2018 12-31-2017 10-K
28 11-08-2017 09-30-2017 10-Q
29 08-08-2017 06-30-2017 10-Q
30 05-09-2017 03-31-2017 10-Q
31 03-09-2017 12-31-2016 10-K
32 11-09-2016 09-30-2016 10-Q
33 08-04-2016 06-30-2016 10-Q
34 05-10-2016 03-31-2016 10-Q
35 03-14-2016 12-31-2015 10-K
36 11-10-2015 09-30-2015 10-Q
37 08-06-2015 06-30-2015 10-Q
38 05-12-2015 03-31-2015 10-Q
39 03-16-2015 12-31-2014 10-K
40 11-04-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 neoleukin-therapeutics-plans-for-1-for-4-reverse-stock-split

The reverse stock split will become effective at 12:02 a.m., Eastern Time on December 18, 2023.

 why-orchard-therapeutics-shares-are-trading-higher-by-around-95-here-are-20-stocks-moving-premarket

Gainers

 neoleukin-therapeutics-plans-1-for-5-reverse-stock-split

The reverse stock split will become effective at 12:01 a.m. Eastern time on September 25, 2023. 

 neoleukin-therapeutics-to-merge-with-neurogene-creates-biotech-firm-focused-on-genetic-medicines-for-neurological-diseases

Privately-held Neurogene Inc has agreed to merge with Neoleukin Therapeutics Inc (NASDAQ: NLTX) in 

 neurogene-neoleukin-therapeutics-enter-definitive-merger-agreement-to-combine-in-an-all-stock-transaction

The combined company is expected to operate under the name Neurogene Inc. and trade on the Nasdaq Capital Market under the tick...

 mizuho-maintains-neutral-on-neoleukin-therapeutics-lowers-price-target-to-15

Mizuho analyst Mara Goldstein maintains Neoleukin Therapeutics (NASDAQ:NLTX) with a Neutral and lowers the price target from...

 us-stocks-turn-lower-sp-500-down-1

U.S. stocks turned lower toward the end of trading, with the Dow Jones dropping around 300 points on Thursday. The Dow traded ...

 why-jdcom-shares-are-trading-lower-by-around-9-here-are-other-stocks-moving-in-thursdays-mid-day-session

Gainers

 us-stocks-pare-gains-bjs-wholesale-club-earnings-top-views

U.S. stocks traded slightly higher midway through trading, with the Nasdaq Composite gaining 20 points on Thursday. The Dow tr...

 neoleukin-therapeutics-seeks-strategic-alternatives-to-layoff-more-in-round-2-within-6-months

Neoleukin Therapeutics Inc (NASDAQ: NLTX) has engaged SVB Securities to assist in reviewing strategic alternatives. 

 why-cassava-sciences-shares-are-trading-higher-by-12-here-are-20-stocks-moving-premarket

Gainers

 reported-late-wednesday-march-08-neoleukin-board-of-directors-approved-a-further-corporate-restructuring-to-preserve-cash-including-a-reduction-in-the-companys-workforce-by-70

In connection with the evaluation of strategic alternatives, the Board of Directors of Neoleukin also approved a further corpor...

 reported-late-wednesday-march-08-neoleukin-therapeutics-provides-strategic-update-and-announces-restructuring-and-leadership-transition-chief-executive-officer-jonathan-drachman-md-will-be-stepping-down-after-a-short-transition

Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computatio...

 guggenheim-downgrades-neoleukin-therapeutics-to-neutral

Guggenheim analyst Charles Zhu downgrades Neoleukin Therapeutics (NASDAQ:NLTX) from Buy to Neutral.

 neoleukin-therapeutics-presents-preclinical-data-on-neo-tra1-at-american-society-of-hematology-annual-meeting

Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computatio...

 stocks-that-hit-52-week-lows-on-thursday

  OnThursday, 137 stocks made new 52-week lows.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION